Morning Overview on MSN
Daraxonrasib, a daily RAS-blocking pill, raised pancreatic cancer survival from 6.7 to 13.2 months with fewer severe side effects than chemo
Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...
Patients with early-stage bladder cancer are often able to maintain their usual routines. Some may experience urinary ...
13hon MSN
Emory University team explores promising new therapy for childhood leukemia with fewer toxic effects
Emory University researchers are studying a treatment that doesn't blast the entire body, but instead, it's designed to find ...
Everyday Health on MSN
Common side effects of FR-Alpha–positive ovarian cancer targeted treatments and how to manage them
Learn about common side effects of FR-alpha–positive ovarian cancer targeted treatments like Elahere, including eye, lung, digestive, and nerve issues, plus management tips.
A majority of cancer patients undergoing radiation therapy experience side effects, according to a survey of more than 3,800 ...
Subcutaneous immunotherapy injections for cancer, such as immune checkpoint inhibitors, are an emerging therapy that may replace some traditional intravenous infusions. Common side effects include ...
A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 ...
As with any treatment for cancer, radiation therapy for colorectal cancer may cause side effects. Some side effects are short term, while others last for longer. Some short-term side effects of ...
CURE spoke with Alexa M. Lantz of Penn State Health about radiation side effects. For patients with cancer who are receiving treatment with radiation therapy, keeping lines of communication open with ...
GlobalData on MSN
NHS to offer precision prostate cancer treatment, cutting radiotherapy doses required
Stereotactic ablative radiotherapy for prostate cancer treatment has been proven effective at five doses versus 20 with ...
A new antibody‑drug conjugate nearly doubles survival and extends overall survival in advanced triple‑negative breast cancer, ...
Researchers found that Keytruda — the focus of ICIJ's recent Cancer Calculus investigation — accounted for nearly half of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results